MedTrace Logo

URMC Related Haplo-identical Donor BMT

NCT02660281 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2021-11-03

No results posted yet for this study

Summary

This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.

Conditions

Interventions

RADIATION

Total Body Irradiation 1200 cGy

1200 cGy TBI in 8 fractions

DRUG

Fludarabine

Fludarabine

DRUG

Pre-Stem Cell Infusion Cyclophosphamide

Cyclophosphamide given prior to the stem cell infusion

DRUG

Pre-Stem Cell Infusion Mesna

Mesna given prior to the stem cell infusion

DRUG

Busulfan

Busulfan

DRUG

Melphalan

Melphalan

PROCEDURE

Stem Cell Infusion

Stem cell infusion

DRUG

Post-Stem Cell Infusion Cyclophosphamide

Cyclophosphamide given after the stem cell infusion

DRUG

Post-Stem Cell Infusion Mesna

Mesna given after the Stem Cell Infusion

DRUG

Thiotepa

Thiotepa

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Jeffrey Andolina, MD · Wilmot Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-10-28
Completion
2021-01-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660281 on ClinicalTrials.gov